Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an exclusive private label distribution agreement (“Agreement”) with global medical technology company Smith+Nephew (LSE:SN, NYSE:SNN). Under the Agreement, Smith+Nephew will market and sell CENTRIO Platelet-Rich Plasma System, their own branded version of Nuo’s underlying Aurix^® System to the United States wound care market. Nuo will continue to be responsible for manufacturing the product.   The Aurix product brand sold separately by Nuo will remain in the market under Nuo’s full control and will be fully available commercially subject to certain customer overlap conditions more fully addressed in the Agreement.